New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence

scientific article published on October 2012

New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1005552924
P356DOI10.1007/BF03261837
P698PubMed publication ID22946769

P2093author name stringStephen Kopecky
P2860cites workRefining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillationQ35003773
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesQ35752573
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).Q42923039
Acute stroke with atrial fibrillation. The Copenhagen Stroke Study.Q51004375
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of CardiologQ51935524
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysisQ28194233
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjectsQ28247385
Dabigatran versus warfarin in patients with atrial fibrillationQ28256895
Adherence to MedicationQ28314923
Validation of Clinical Classification Schemes for Predicting StrokeQ29028208
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyQ29614197
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationQ29614696
Apixaban versus warfarin in patients with atrial fibrillationQ29617563
A systematic review of the associations between dose regimens and medication complianceQ30719289
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Q34012421
Apixaban in patients with atrial fibrillationQ34163710
P433issue5
P921main subjectatrial fibrillationQ815819
P304page(s)287-294
P577publication date2012-10-01
P1433published inAmerican journal of cardiovascular drugsQ2555367
P1476titleNew anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence
P478volume12

Reverse relations

cites work (P2860)
Q34834319Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model
Q42697095Rates and predictors of 5-year survival in a national cohort of asymptomatic elderly patients undergoing carotid revascularization
Q38107177Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation
Q37004184Who Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory Models

Search more.